Milkiewicz P, Chilton A P, Hubscher S G, Elias E
Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, UK.
Gut. 2003 Feb;52(2):300-3. doi: 10.1136/gut.52.2.300.
We report two cases of antidepressant induced cholestasis.
We describe the first reported case of acute cholestasis due to citalopram (selective serotonin reuptake inhibitor) occurring in a patient who also experienced obstetric cholestasis in association with each of three pregnancies; in a second patient cholestasis developed due to dothiepin (tricyclic antidepressant), and six years later due to paroxetine. In both cases liver biopsies showed features of a "pure" cholestasis with total resolution within 1-6 months after withdrawal of the causative drug. Immunostaining for the canalicular transporter, multidrug resistant protein 2 (MRP2), responsible for biliary secretion of several organic anions including bilirubin glucuronides, showed sustained expression in both biopsies as well as relocalisation with appearance of strong staining of the basolateral membrane of the hepatocyte. This finding has also not been reported previously.
We postulate that intracellular redistribution of MRP2 may reflect an adaptive compensatory mechanism which helps in the elimination of the drug or its cholestatic metabolites from the hepatocyte back to the sinusoidal space and subsequent excretion in urine. Changes seen in these two patients differ from findings previously reported in rats where downregulation of mrp2 occurs in response to experimentally induced cholestasis. We speculate that the rat is more advanced than humans in its ability to downregulate canalicular transporter expression as protection against progressive intrahepatic cholestasis.
我们报告两例抗抑郁药引起的胆汁淤积症。
我们描述了首例因西酞普兰(选择性5-羟色胺再摄取抑制剂)导致的急性胆汁淤积症病例,该患者在三次妊娠中均并发产科胆汁淤积症;第二例患者胆汁淤积症由多塞平(三环类抗抑郁药)引起,六年后又因帕罗西汀引发。两例患者肝脏活检均显示“单纯性”胆汁淤积症特征,停用致病药物后1 - 6个月内完全消退。对负责包括胆红素葡萄糖醛酸苷在内的多种有机阴离子胆汁分泌的小管转运体多药耐药蛋白2(MRP2)进行免疫染色,结果显示在两次活检中MRP2均持续表达,且出现重新定位,表现为肝细胞基底外侧膜强染色。这一发现此前也未见报道。
我们推测MRP2的细胞内重新分布可能反映一种适应性代偿机制,有助于将药物或其胆汁淤积性代谢产物从肝细胞清除回到肝血窦间隙并随后经尿液排泄。这两名患者出现的变化与先前在大鼠实验中所报道的结果不同,在大鼠实验性胆汁淤积症中mrp2会下调。我们推测大鼠在下调小管转运体表达以预防进行性肝内胆汁淤积症方面比人类更先进。